Unveiling the multitargeted potency of Sodium Danshensu against cervical cancer: a multitargeted docking-based,

Saad Alghamdi1, Hanadi M Baeissa2, Mohammad Azhar Kamal3

  • 1Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.

Insights

This study identified Sodium Danshensu as a potential multitargeted drug for cervical cancer (CC). This natural compound effectively targets key proteins involved in CC development, showing promise for new therapeutic strategies.

Area of Science:

  • Biochemistry
  • Computational Chemistry
  • Oncology

Background:

  • Cervical cancer (CC) remains a leading cause of cancer deaths in women globally.
  • Existing treatments for CC have limitations, necessitating the development of novel therapeutic agents.

Purpose of the Study:

  • To identify potential multitargeted drug candidates for cervical cancer (CC) by screening FDA-approved compounds.
  • To evaluate the efficacy of identified compounds against key proteins involved in CC progression.

Main Methods:

  • Utilized molecular docking algorithms (HTVS, SP, XP) to screen an FDA library against Mitotic kinesin-like protein 1, Cyclin B1, DNA polymerase, and MCM10-ID.
  • Assessed binding affinity, pharmacokinetics, and interaction fingerprinting of potential drug candidates.
  • Performed 100 ns molecular dynamics simulations to validate the stability of protein-ligand complexes.

Main Results:

  • Sodium (Na) Danshensu, a natural phenolic compound, was identified as a promising candidate.
  • Na-danshensu demonstrated strong binding affinity (docking scores -5.892 to -13.103 Kcal/mol) and stable complex formation with target proteins.
  • Molecular dynamics simulations confirmed the stability of the Na-danshensu-protein complexes.

Conclusions:

  • Na-danshensu shows significant potential for drug repurposing as a multitargeted therapeutic agent against cervical cancer (CC).
  • The compound's ability to form stable complexes with multiple CC-related proteins supports its candidacy for novel CC drug development.